<DOC>
	<DOCNO>NCT00620659</DOCNO>
	<brief_summary>The purpose study determine safety efficacy MK0249 treat refractory excessive daytime sleepiness ( EDS ) patient Obstructive Sleep Apnea/Hypopnea Syndrome ( OSA/HS ) use nasal continuous positive airway pressure ( nCPAP ) therapy .</brief_summary>
	<brief_title>Treatment Refractory Excessive Daytime Sleepiness Patients With Obstructive Sleep Apnea/Hypopnea Syndrome ( OSA/HS ) Using Nasal Continuous Positive Airway Pressure ( nCPAP ) Therapy ( 0249-015 )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<criteria>Patient male female least 18 year old less 65 year old Patient must diagnosis Obstructive Sleep Apnea/Hypopnea Syndrome Patient use nCPAP treatment least 2 month prior Visit 1 Patient willing stay sleep laboratory 4 full day night observation assessment Patient willing refrain nap duration study Patient pregnant , breastfeeding , plan become pregnant within next 4 month Patient participate study investigational compound device within 30 day sign informed consent Patient asthmarelated visit emergency room hospitalization within 6 month Visit 1 Patient donate receive blood product within 8 week sign consent planning either duration study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>